The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Abstract
Long-term treatment with glucocorticoids (GCs) leads to a rapid bone loss and to a greater risk of fractures. To evaluate the specific effects of this treatment on cancellous bone remodeling, structure, and microarchitecture, we compared 22 transiliac biopsy specimens taken in postmenopausal women (65 ± 6 years) receiving GCs (≥7.5 mg/day, for at least 6 months) and 22 biopsy specimens taken in age-matched women with postmenopausal osteoporosis (PMOP), all untreated and having either at least one vertebral fracture or a T score < −2.5 SD. On these biopsy specimens, we measured static and dynamic parameters reflecting trabecular bone formation and resorption. Also, we performed the strut analysis and evaluated the trabecular bone pattern factor (TBPf), Euler number/tissue volume (E/TV), interconnectivity index (ICI), and marrow star volume (MaSV). Glucocorticoid-induced osteoporosis (GIOP), when compared with PMOP, was characterized by lower bone volume (BV/TV), trabecular thickness (Tb.Th), wall thickness (W.Th), osteoid thickness (O.Th), bone formation rate/bone surface (BFR/BS), adjusted mineral apposition rate/bone surface (Aj.AR/BS), and higher ICI and resorption parameters. After adjustment for BV/TV, the W.Th remained significantly lower in GIOP (p < 0.0001). The active formation period [FP(a+)] was not different. Patients with GIOP were divided into two groups: high cumulative dose GCs (HGCs; 23.7 ± 9.7 g) and low cumulative dose GCs (LGCs; 2.7 ± 1.2 g). HGC when compared with LGC was characterized by lower W.Th (p < 0.05), BV/TV (p < 0.001), Tb.Th (p < 0.05), trabecular number (Tb.N; p < 0.05), FP(a+) (p < 0.05), and nodes (p < 0.05), and higher E/TV (p < 0.05), ICI (p < 0.005), and TBPf (p < 0.05). When HGC was compared with PMOP, the results were similar except for the MaSV, which was significantly higher (p < 0.005). In summary, GIOP was characterized by lower formation and higher resorption than in PMOP, already present after LGC. With HGCs, these changes were associated with a more dramatic bone loss caused by a major loss of trabecular connectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the skeletal response to prednisolone in these rats shared several similarities to changes observed in humans, including significantly decreased BMD (243), histological evidence of increased bone resorption (194), and biochemical evidence of suppressed bone formation (244, 267, 268).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [194]
In the citing paper
“The prednisolonerelated increase in bone volume in rats, confirmed in a study described immediately below (262), is not consistent with histological data from patients with glucocorticoid-induced osteoporosis (194) and is a recognized limitation of the model (251).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [194]
Citations
Cites
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,344
Self-citationBone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Self-citationPARFITT, A. M., Mathews, C. H. E., Villanueva, A. R., Kleerekoper, M., Frame, B., & Rao, D. S. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111096 · Cited by 1,542
The direct examination of three-dimensional bone architecture in vitro by computed tomography
Feldkamp, L. A., Goldstein, S. A., Parfitt, M. A., Jesion, G., & Kleerekoper, M. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040103 · Cited by 1,073
Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,063
Steroid-Induced Fractures and Bone Loss in Patients with Asthma
Adinoff, A., & Hollister, J. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090502 · Cited by 662
Trabecular bone pattern factor—a new parameter for simple quantification of bone microarchitecture
Hahn, M. P., Vogel, M., Pompesius-Kempa, M., & Delling, G. (1992) · Bone · doi:10.1016/8756-3282(92)90078-b · Cited by 540
Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis
Laan, R., van Riel, P. L. C. M., van de Putte, L. B. A., van Erning, L. J. T. O., Hof, M. A. V., & Lemmens, J. A. M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00001 · Cited by 410
ROSS, E. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92749-0 · Cited by 390
New Developments in the Pathogenesis and Treatment of Steroid-Induced Osteoporosis
Manolagas, S. C., & Weinstein, R. S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.7.1061 · Cited by 382
Research works printed but not linked: 2
- Le, 1992, Computerized quantitative analysis of the interconnectivity of porous biomaterials, Acta Stereol, 11, 267
- Gallagher, 1996, Osteoporosis, 1191
Cited by
Sorted by citations
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Glucocorticoid-induced osteoporosis: an update
Compston, J. E. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 494
Mechanisms of Glucocorticoid Action in Bone
CANALIS, E., & DELANY, A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04204.x · Cited by 406
Weinstein, R. S., Chen, J., Powers, C. C., Stewart, S. A., Landes, R. D., Bellido, T., Jilka, R. L., PARFITT, A. M., & Manolagas, S. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14538 · Cited by 397
Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355
Fracture risk with intermittent high‐dose oral glucocorticoid therapy
de Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C. C., & van Staa, T. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22294 · Cited by 297
Animal models for fracture treatment in osteoporosis
Egermann, M., Goldhahn, J., & Schneider, E. H. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1859-7 · Cited by 260
The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis
van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 257
Hartmann, K., Koenen, M., Schauer, S., Wittig-Blaich, S., Ahmad, M., Baschant, U., & Tuckermann, J. P. (2016) · Physiological Reviews · doi:10.1152/physrev.00011.2015 · Cited by 251
Perspectives on glucocorticoid-induced osteoporosis
CANALIS, E. M., Bilezikian, J. P., Angeli, A., & Giustina, A. (2003) · Bone · doi:10.1016/j.bone.2003.11.026 · Cited by 244
Chavassieux, P., Seeman, E., & Delmas, P. D. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0029 · Cited by 224
Self-citationMaurer, M., Riesen, W., Muser, J. M., Hulter, H. N., & Krapf, R. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00212.2002 · Cited by 211
Bone microarchitecture as an important determinant of bone strength
Carbonare, L. D., & Giannini, S. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03350919 · Cited by 210
Self-citationShevroja, E., Reginster, J., Lamy, O., Al‐Daghri, N. M., Chandran, M., Demoux, A., Kohlmeier, L., Lecart, M.-P., Messina, D., Camargos, B. M., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06817-4 · Cited by 208
Cooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., & Stewart, P. M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.979 · Cited by 200
Kitase, Y., Barragan, L., Qing, H., Kondoh, S., Jiang, J. X., Johnson, M. L., & Bonewald, L. F. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.168 · Cited by 199
Management of glucocorticoid-induced osteoporosis
Compston, J. E. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.259 · Cited by 193
Rubin, M. R., & Bilezikian, J. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-012101 · Cited by 191
Glucocorticoid-induced osteoporosis: 2019 concise clinical review
Adami, G., & Saag, K. G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04906-x · Cited by 191
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
Mechanisms of glucocorticoid-induced osteoporosis.
Canalis, E. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00013 · Cited by 164
Pereira, R. C., Delany, A. M., & CANALIS, E. M. (2002) · Bone · doi:10.1016/s8756-3282(02)00687-7 · Cited by 163
Mechanisms of glucocorticoid action in bone
CANALIS, E. M. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0017-7 · Cited by 160
Glucocorticoid dose determines osteocyte cell fate
Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis
Kanis, J. A., Stevenson, M., McCloskey, E. V., Davis, S., & Lloyd-Jones, M. (2007) · Health Technology Assessment · doi:10.3310/hta11070 · Cited by 153
Glucocorticoid-induced osteoporosis
Saag, K. G. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00064-6 · Cited by 145
Saha, P. K., & Wehrli, F. W. (2004) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2003.819925 · Cited by 145
Glucocorticoid-Induced Osteoporosis: Summary of a Workshop
CANALIS, E. M., & Giustina, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8066 · Cited by 132
Ominsky, M. S., Li, X., Asuncion, F., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M. S., Tan, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 132
Graeff, C., Marín, F., Petto, H., Kayser, O., Reisinger, A., Peña, J. A., Zysset, P. K., & Glüer, C. (2012) · Bone · doi:10.1016/j.bone.2012.10.036 · Cited by 128
Influence of Glucocorticoids on Human Osteoclast Generation and Activity
Sivagurunathan, S., Muir, M. M., Brennan‐Speranza, T. C., Seale, J. P., & Mason, R. S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041233 · Cited by 125
Endocrine manifestations in Langerhans cell histiocytosis
Makras, P., Alexandraki, K., Chrousos, G. P., Grossman, A. B., & Kaltsas, G. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.003 · Cited by 124
Adverse Effects of Corticosteroids on Bone Metabolism: A Review
Mitra, R. (2011) · PM&R · doi:10.1016/j.pmrj.2011.02.017 · Cited by 122
Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 116
Important Determinants of Bone Strength
Friedman, A. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000208612.33819.8c · Cited by 111
A rapid, high content, in vivo model of glucocorticoid‐induced osteoporosis
Barrett, R., Chappell, C., Quick, M., & Fleming, A. (2006) · Biotechnology Journal · doi:10.1002/biot.200600043 · Cited by 104
Osteoporosis Associated with Excess Glucocorticoids
Shaker, J. L., & Lukert, B. P. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.014 · Cited by 100
11β-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone
Cooper, M. S., Blumsohn, A., Goddard, P. E., Bartlett, W. A., Shackleton, C. H. L., Eastell, R., Hewison, M., & Stewart, P. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-022025 · Cited by 97
Glucocorticoid-Induced Osteoporosis: Why Kids Are Different
Ward, L. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00576 · Cited by 96
Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle
Søe, K., & Delaissé, J. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.113 · Cited by 97
Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes
Gado, M., Baschant, U., Hofbauer, L. C., & Henneicke, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.835720 · Cited by 95
Mostoufi‐Moab, S., Brodsky, J. L., Isaacoff, E. J., Tsampalieros, A. K., Ginsberg, J. P., Zemel, B. S., Justine Shults, A., & Leonard, M. B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2393 · Cited by 88
The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats
Liu, Z., Zhang, R., Li, C., Ma, X., Liu, L., Wang, J.-P., & Mei, Q. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.02.025 · Cited by 88
Pistoia, W. (2003) · Bone · doi:10.1016/j.bone.2003.06.003 · Cited by 88
Wetzsteon, R. J., Justine Shults, A., Zemel, B. S., Gupta, P., Burnham, J. M., Herskovitz, R. M., Howard, K. M., & Leonard, M. B. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081101 · Cited by 87
Vinolas, H., Grouthier, V., Mehsen-Cêtre, N., Boisson, A., Winzenrieth, R., Schaeverbeke, T., Mesguich, C., Bordenave, L., & Tabarin, A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13743 · Cited by 87
A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children
Hansen, K. E., Kleker, B., Safdar, N., & Bartels, C. M. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.02.002 · Cited by 87
Glucocorticoids and osteocyte autophagy
Yao, W., Dai, W., Jiang, J. X., & Lane, N. E. (2013) · Bone · doi:10.1016/j.bone.2013.01.034 · Cited by 82
Rehman, Q., Lang, T., Modin, G. W., & Lane, N. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10277 · Cited by 82
Glucocorticoid‐induced osteoporosis: lessons from Cushing's syndrome
Tóth, M., & Grossman, A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12189 · Cited by 81
Cortisol regulates the expression of Notch in osteoblasts
Pereira, R. M. R., Delany, A. M., Durant, D., & CANALIS, E. M. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10125 · Cited by 80
Justesen, J., Mosekilde, L., Holmes, M. C., Stenderup, K., Gasser, J. A., Mullins, J. J., Seckl, J. R., & Kassem, M. S. (2004) · Endocrinology · doi:10.1210/en.2003-1427 · Cited by 78
Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis
Gu, G., Hentunen, T. A., Nars, M., Härkönen, P. L., & Väänänen, H. K. (2005) · APOPTOSIS · doi:10.1007/s10495-005-1893-0 · Cited by 78
Bone status in glucocorticoid-treated men and women
Leib, E. S., & Winzenrieth, R. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3211-1 · Cited by 73
Histomorphometric analysis of glucocorticoid-induced osteoporosis
Carbonare, L. D., Bertoldo, F., Valenti, M. T., Zenari, S., Zanatta, M., Sella, S., Giannini, S., & Cascio, V. L. (2005) · Micron · doi:10.1016/j.micron.2005.07.009 · Cited by 71
Self-citationSensitivity of bone to glucocorticoids
Cooper, M. S. (2004) · Clinical Science · doi:10.1042/cs20040070 · Cited by 68
Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma
Francucci, C. M., Pantanetti, P., Garrapa, G. G., Massi, F., Arnaldi, G., & Mantero, F. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01602.x · Cited by 65
Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis
Hansen, K. E., Wilson, H. A., Zapalowski, C., Fink, H. A., Minisola, S., & Adler, R. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.362 · Cited by 65
Tsampalieros, A. K., Gupta, P., Denburg, M., Justine Shults, A., Zemel, B. S., Mostoufi‐Moab, S., Wetzsteon, R. J., Herskovitz, R. M., Whitehead, K., & Leonard, M. B. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1785 · Cited by 65
Effects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitro
Zhang, R., Pan, Y., Hu, S., Kong, X., Wang, J., & Mei, Q. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.04.031 · Cited by 65
Feber, J., Gaboury, I., Ni, A., Alos, N., Arora, S., Bell, L., Blydt‐Hansen, T. D., Clarson, C. L., Filler, G., Hay, J., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1621-2 · Cited by 66
Achyranthes bidentata root extract prevent OVX-induced osteoporosis in rats
Zhang, R., Hu, S., Li, C., Zhang, F., Gan, H., & Mei, Q. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.05.034 · Cited by 63
Glucocorticoid-induced osteoporosis
Clowes, J. A., Peel, N. F. A., & Eastell, R. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200107000-00015 · Cited by 62
Lian, K.-C., Lang, T., Keyak, J. H., Modin, G. W., Rehman, Q., Do, L., & Lane, N. E. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1736-9 · Cited by 62
Mostoufi‐Moab, S., Ginsberg, J. P., Bunin, N., Zemel, B. S., Justine Shults, A., & Leonard, M. B. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1499 · Cited by 60
Rangaswamaiah, S., Gangathimmaiah, V., Nordenstrom, A., & Falhammar, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00493 · Cited by 59
Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease
Carbonare, L. D., Mattè, A., Valenti, M. T., Siciliano, A., Mori, A., Schweiger, V., Zampieri, G., Perbellini, L., & Franceschi, L. D. (2015) · Blood · doi:10.1182/blood-2015-04-641969 · Cited by 58
Self-citationKaji, H., Yamauchi, M., Chihara, K., & Sugimoto, T. (2006) · Endocrine Journal · doi:10.1507/endocrj.53.27 · Cited by 58
Secondary osteoporosis in patients with an osteoporotic fracture
Kok, C., & Sambrook, P. N. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.006 · Cited by 57
Sutter, S. A., Nishiyama, K. K., Kepley, A. L., Zhou, B., Wang, J., McMahon, D. J., Guo, X., & Stein, E. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2177 · Cited by 57
Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS
Zhang, S., Liu, Y., & Liang, Q. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8461 · Cited by 58
Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases
Gluck, O. S., & Colice, G. (2004) · CHEST Journal · doi:10.1378/chest.125.5.1859 · Cited by 57
Zarrinkalam, M. R., Mulaibrahimovic, A., Atkins, G. J., & Moore, R. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1672-4 · Cited by 56
Hwang, J.-Y., Lee, S. H., Kim, G. S., Koh, J.-M., Go, M. J., Kim, Y.-J., Kim, H.-C., Kim, T.-H., Hong, J. M., Park, E. K., et al. (2009) · Bone · doi:10.1016/j.bone.2009.07.080 · Cited by 55
Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis
Kalpakcioglu, B. B., Engelke, K., & Genant, H. K. (2011) · Bone · doi:10.1016/j.bone.2011.02.005 · Cited by 57
Glucocorticoid-induced osteoporosis
Tamura, Y., Okinaga, H., & Takami, H. E. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.08.018 · Cited by 56
Yamamoto, M., Yamaguchi, T., Yamauchi, M., Kaji, H., & Sugimoto, T. (2007) · Calcified Tissue International · doi:10.1007/s00223-007-9003-7 · Cited by 54
Ikeda, S., Morishita, Y., Tsutsumi, H., Ito, M., Shiraishi, A., Arita, S., Akahoshi, S., Narusawa, K., & Nakamura, T. (2003) · Bone · doi:10.1016/s8756-3282(03)00263-1 · Cited by 53
Iacopo, C., Falchetti, A., Merlotti, D., Cristina, E.-V., & Gennari, L. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1772051 · Cited by 56
Osteocyte viability with glucocorticoid treatment: relation to histomorphometry
Sambrook, P. N., Hughes, D. R., Nelson, A. E., Robinson, B. G., & Mason, R. S. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.008839 · Cited by 53
Do different locomotor modes during growth modulate trabecular architecture in the murine hind limb?
Carlson, K. J., Lublinsky, S., & Judex, S. (2008) · Integrative and Comparative Biology · doi:10.1093/icb/icn066 · Cited by 52
Rydziel, S., Delany, A. M., & CANALIS, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311984200 · Cited by 52
Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease
Guichelaar, M. M., Malinchoc, M., Sibonga, J. D., Clarke, B. L., & Hay, J. E. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2190 · Cited by 50
Glucocorticoid-induced osteoporosis
Silverman, S. L., & Lane, N. E. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0005-4 · Cited by 50
Tang, X., Qin, L., Kwok, A. W. L., ZHU, T. Y., Kun, E. W. L., Hung, V. W.-Y., Griffith, J. F., Leung, P., Li, E. K., & Tam, L. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2177-5 · Cited by 51
Bone density and microarchitecture in endogenous hypercortisolism
dos Santos, C. V., Neto, L. V., Madeira, M., Coelho, M. C. A., de Mendonça, L. M. C., Paranhos‐Neto, F. D. P., Lima, I. C. B., Gadelha, M. R., & Farias, M. L. F. (2015) · Clinical Endocrinology · doi:10.1111/cen.12812 · Cited by 49
Steering the osteoclast through the demineralization–collagenolysis balance
Søe, K., Merrild, D. M. H., & Delaissé, J. (2013) · Bone · doi:10.1016/j.bone.2013.06.007 · Cited by 49
Choi, Y. J., Chung, Y., Suh, C., Jung, J.-Y., & Kim, H. (2017) · Medicine · doi:10.1097/md.0000000000008661 · Cited by 49
Edwards, B. J.-A., Raisch, D. W., Shankaran, V., McKoy, J. M., Gradishar, W. J., Bunta, A. D., Samaras, A. T., Boyle, S. N., Bennett, C. L., West, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1595 · Cited by 51
Protective effects of necrostatin-1 on glucocorticoid-induced osteoporosis in rats
Feng, M., Zhang, R., Gong, F., Yang, P., Fan, L., Ni, J., Bi, W., Zhang, Y., Wang, C., & Wang, K. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.09.005 · Cited by 48
Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments
Lafage‐Proust, M., Boudignon, B. M., & Thomas, T. (2003) · Joint Bone Spine · doi:10.1016/s1297-319x(03)00016-2 · Cited by 47
Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks.
Townsend, H. B., & Saag, K. G. (2004) · PubMed · Cited by 47
Nägele, E., Kühn, V., Vogt, H., Link, T. M., Müller, R., Lochmüller, E., & Eckstein, F. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0151-8 · Cited by 46
Luisetto, G., Zangari, M., Camozzi, V., Boscaro, M., Sonino, N., & Fallo, F. (2001) · Osteoporosis International · doi:10.1007/s001980170025 · Cited by 45
A sheep model for fracture treatment in osteoporosis: Benefits of the model versus animal welfare
Egermann, M., Goldhahn, J., Holz, R. C., Schneider, E. H., & Lill, C. A. (2008) · Laboratory Animals · doi:10.1258/la.2007.007001 · Cited by 44
Han, Y., Zhang, L., Xing, Y., Zhang, L., Chen, X., Tang, P., & Chen, Z. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3270 · Cited by 44
Treatment options for glucocorticoid-induced osteoporosis
Chiodini, I., Merlotti, D., Falchetti, A., & Gennari, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1721467 · Cited by 44
Chen, L., Shi, X., Weng, S., Xie, J., Tang, J., Yan, D., Wang, B.-Z., Xie, Z.-J., Wu, Z., & Yang, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01209 · Cited by 44
Liu, X., Lei, W., Wu, Z., Cui, Y., Han, B.-J., Fu, S., & Jiang, C. (2011) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2011.06.010 · Cited by 43
Metadata
- Authors
- Carbonare, L. D., Arlot, M. E., Chavassieux, P. M., Roux, J. P., Portero, N. R., & Meunier, P. J.
- Affiliations
- Inserm (FR)
- Institut National de la Santé et de la Recherche Médicale Unit 403 and Laboratoire d'Histodynamique Osseuse, Lyon, France
- Corresponding author
- Carbonare, L. Dalle
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-01-01
- Volume
- 16
- Issue
- 1
- Pages
- 97-103
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1972567404
- Cited by
- 309
- References
- 40
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 9 · 2020: 13 · 2019: 11 · 2018: 14 · 2017: 7 · 2016: 5 · 2015: 12 · 2014: 12 · 2013: 12 · 2012: 16
- FWCI
- 20.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- glucocorticoid-induced osteoporosis, postmenopausal osteoporosis, trabecular bone microarchitecture, bone remodeling, trabecular bone, bone formation rate, bone resorption, cumulative glucocorticoid dose, bone loss, trabecular thickness, wall thickness, Euler characteristic
- MeSH terms
- Aged, Biopsy, Bone and Bones, Female, Glucocorticoids, Histocytochemistry, Humans, Ilium, Middle Aged, Osteoporosis, Osteoporosis, Postmenopausal, Bone Remodeling, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review